Avelumab
Toxicities
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities, but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Creatine phosphokinase elevations (grade 1 or 2) 1% to 7%, 5, 7 (grade 3 or 4) 1% to 2% 2,5,9 ; embolic stroke (grade 3 or 4) 1% 8 ; hypertension (grade 3 or 4) 1% 8 ; hypovolemia (grade 3 or 4) 1%. 8 B. Central Nervous System: Syncope (grade 3 or 4) 1%. 8 C. Constitutional: Asthenia (grade 1 or 2) 8% to 9%, 5, 9 (grade 3 or 4) 2% 9 ; chills (grade 1 or 2) 7% to 15% 2,7,8 ; fall (grade 3 or 4) 1% 8 ; fatigue (all grades) 15% to 20%, 1,6 (grade 1 or 2) 14% to 67%, 2,3,7-9 (grade 3 or 4) 2% to 3% 1, 4, 6 ; fever (all grades) 11%, 2 (grade 1 or 2) 27% 7 ; influenza-like illness (grade 1 or 2) 20%. 7 D. Dermatologic: Maculopapular rash (grade 1 or 2) 6% 5 ; pruritus (grade 1 or 2) 7% 9 ; psoriasis (grade 1 or 2) 1% 8 ; rash (grade 1 or 2) 7% to 9%. 5, 7, 9 E. Endocrine/metabolic: Adrenal insufficiency (grade 1 or 2) 1% 8 ; amylase elevations (grade 1 or 2) 1%, 8 (grade 3 or 4) 1% 8 ; autoimmune reaction (any type, grade 3 or 4) 14% 7 ; cholesterol elevations (grade 3 or 4) 1% 5 ; hyperthyroidism (grade 1 or 2) 2% 5 ; hypoglycemia (grade 1 or 2) 13% 7 ; hyponatremia (grade 3 or 4) 1% 8 ; hypothyroidism (grade 1 or 2) 1% to 7% 5, 6, 8, 9 ; lipase elevations (grade 1 or 2) 1%, 8 (grade 3 or 4) 2% 3, 8 ; type I diabetes mellitus (grade 1 or 2) 1%. 5 F. Gastrointestinal: Colitis (grade 3 or 4) 8% 2 ; constipation (grade 1 or 2) 2%, 8 (grade 3 or 4) 1% 8 ; decreased appetite (grade 1 or 2) 2% to 7%, 5, 8, 9 (grade 3 or 4) 2% 9 ; diarrhea (grade 1 or 2) 7% to 13% 3,5,7-9 ; nausea (all grades) 14%, 1 (grade 1 or 2) 9% to 13% 5,7-9 ; vomiting (grade 1 or 2) 5%. 8 G. Hematologic: Anemia (grade 1 or 2) 3%, 8 (grade 3 or 4) 1% to 3% 1, 4, 8 ; lymphopenia (grade 1 or 2) 20%, 7 (grade 3 or 4) 2% to 7% 2,5,7 ; neutropenia (grade 3 or 4) 1% 8 ; systemic inflammatory response syndrome (grade 3 or 4) 1% 8 ; thrombocytopenia (grade 3 or 4) 3%. 4 H. Hepatic: Aminotransferase elevations (grade 3 or 4) 1% 5, 8 ; alanine aminotransferase (ALT) elevations (grade 1 or 2) 2%, 9 (grade 3 or 4) 7% 7 ; aspartate aminotransferase (AST) elevations (grade 1 or 2) 2%, 9 (grade 3 or 4) 2% to 7% 7,9 ; autoimmune hepatitis (grade 3 or 4) 2% 1 ; gamma-glutamyl transferase elevations (grade 1 or 2) 1%, 8 (grade 3 or 4) 1% to 2%. 1,2,8 I. Hypersensitivity: Allergic rhinitis (grade 1 or 2) 7% 7 ; anaphylactic reaction (grade 3 or 4) 1% 8 ; infusion reactions (all grades) 12% to 17%, 1,6 (grade 1 or 2) 7% to 38%, 2-5,7-9 (grade 3 or 4) 2%. 6 
Dosage Modifications

A. Hepatic
For mild hepatic impairment (bilirubin ≤ upper limit of normal [ULN] and AST > ULN; or bilirubin 1-1.5 times ULN and any AST) or moderate hepatic impairment (bilirubin 1.5-3 times ULN), no dose adjustments are necessary. 10 Avelumab data in patients with severe hepatic impairment (bilirubin >3 times ULN) are limited. 10 
B. Renal
For mild to severe renal impairment (estimated glomerular filtration rate: 15-89 mL/min/1.73 m 2 ), no dose adjustments are necessary. 10
Ribociclib
Synonyms: LEE011, Kisqali
Mechanism of Action
Ribociclib is an orally bioavailable and selective inhibitor of cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor, which prevents CDK4/6-retinoblastoma (Rb) phosphorylation. Inhibition of Rb results in G1 cell cycle arrest. [11] [12] [13] Ribociclib acts synergistically with aromatase inhibitors in preclinical models of estrogen receptor-positive breast cancer, a malignancy in which CDK-4/6 is frequently overexpressed. [12] [13] [14] [15] Pharmacokinetics Following oral dosing, ribociclib is rapidly absorbed with a median time to maximum serum concentration (T max ) of 1 to 6 hours. 11, 12, 15 With daily oral dosing, steady state is reached by about day 8. 11, 12, 15 At 600 mg/d oral dosing, ribociclib's mean effective half-life based on accumulation ratio (T 1/2 acc) is 32 to 32.6 hours 11, 15 and geometric mean apparent oral CL is 25.5 L/h. 15 On day 14 of 600 mg/d oral dosing, the mean C max , AUC 0-6h , and AUC 0-24h were 3083 ng/mL, 13 348 ng·h/mL, and 38 896 ng·h/mL, respectively. 12 Oral administration of 600-mg ribociclib in the approved dosage form combined with a high-fat meal has no effect on the rate and extent of ribociclib absorption. 15 Plasma protein binding is about 70%, and the apparent V d is 1090 L. 15 Ribociclib undergoes extensive hepatic metabolism mainly via CYP3A4, with the main metabolic pathway being oxidation. 15 Clinical activity of ribociclib is mainly due to parent drug, with very small contribution from multiple circulating metabolites. 15 Elimination is mainly via feces at 69%, with 23% of dose recovered from urine. 15 The extensive metabolism of ribociclib is reflected by the unchanged drug fractions of 17% and 12% found in feces and urine, respectively. 15 Selected therapeutic regimens of ribociclib appear in Table 2 . 
Stability
Store at 20°C to 25°C (68°F-77°F Conforms to dosing information listed in the manufacturer's labeling when taken in combination with an aromatase inhibitor.
